• PDF / 169,272 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 50 Downloads / 148 Views

DOWNLOAD

REPORT

---

1 S

Mixed-renal syndrome and thrombocytopenia: 2 case reports In a retrospective, observational cohort study involving 547 patients with chronic rheumatic diseases, 2 patients [ages and sexes not stated] were described, who developed mixed-renal syndrome with nephrotic levels of proteinuria and haematuria (one patient) or thrombocytopenia (one patient) during treatment with etanercept or infliximab for the chronic rheumatic diseases [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. Patient 1: The patient with juvenile idiopathic arthritis, started receiving treatment with etanercept; however, the patient developed features of the mixed-renal syndrome with nephrotic levels of proteinuria and haematuria, which were considered as etanercept therapy related. The patient required hospitalisation. Patient 2: The patient with juvenile idiopathic arthritis started receiving treatment with infliximab; however, the patient developed treatment-related thrombocytopenia. Said MA, et al. Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center 803517516 cohort. Advances in Rheumatology 60: 53, No. 1, 5 Nov 2020. Available from: URL: http://doi.org/10.1186/s42358-020-00154-4

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832